Protalix BioTherapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $-7.5M | $16.9M |
| Jun 2022 | — | $-9.9M | $12.5M |
| Sep 2022 | — | $-11.5M | $10.7M |
| Dec 2022 | — | $-10.6M | $17.1M |
| Mar 2023 | — | $1.0M | $33.0M |
| Jun 2023 | — | $39.0M | $48.2M |
| Sep 2023 | — | $38.2M | $20.4M |
| Dec 2023 | — | $33.6M | $23.6M |
| Mar 2024 | — | $29.8M | $27.2M |
| Jun 2024 | — | $28.6M | $23.4M |
| Sep 2024 | — | $32.4M | $27.4M |
| Dec 2024 | — | $43.2M | $19.8M |
| Mar 2025 | — | $45.2M | $19.5M |
| Jun 2025 | — | $49.9M | $17.9M |
| Sep 2025 | — | $52.9M | $13.6M |
| Dec 2025 | — | $48.2M | $14.7M |
| Mar 2026 | — | $67.2M | $41.0M |
| Jun 2026 | — | $71.4M | $27.4M |